Request for proposal RFP - 025357 - IN VITRO EFFICACY STUDY IN A LARGE PANEL OF CANCER MODELS INCLUDING ORGANOID SCREEN - Update no 2 - adding answers on received questions - appendix 5

In connection with the project „Clinical trial of the first phase (Ia/Ib) of a fusion protein with a dual anticancer mechanism”, financed from Medical Research Agency (nr. 2022/ABM/05/00006-00) operating under §8 of the subsidy agreement, Adamed Pharma S.A.  invites you to submit offers for the execution of the below defined subject of the contract.

Study Sponsor (Contracting Authority): Adamed Pharma S.A.

Object of the Contract

The object of the Contract is:

Task 1. In vitro 2D cytotoxicity assay in a panel of cancer cell lines

Assessment of in vitro anti-tumor efficacy of biological compounds in a panel of max. 400 cancer cell lines of several cancer types chosen by the sponsor.

Task 2. In vitro 2D cytotoxicity assay in a panel of patient-derived cancer cells

Assessment of in vitro anti-tumor efficacy of biological compounds in a panel of max. 30 patient-derived cancer cell line of several cancer types chosen by the sponsor.

Task 3. In vitro 3D cytotoxicity assay in a panel of patient-derived organoids

Assessment of in vitro anti-tumor efficacy of biological compounds in a panel of max. 50 patient-derived organoids of several cancer types chosen by the sponsor.

For all three tasks:

The assessment should be performed by conducting a viability assay based on detection of ATP. Cell viability should be measured after 72-hour incubation with test items. Efficacy of the test items should be reported as IC50 values derived from minimum 9-point concentration-effect curve. Study should be run in three independent biological repetitions. Assay performance shall be validated by inclusion of chemotherapeutic agent (standard of care) and vehicle controls on each plate.

The available models should be well-characterized and have at least the following: phenotypic and genotypic data, growth curves, patient information (for patient-derived models), and data from treatment with the standard of care. As part of the verification process for the availability of appropriate models, the bidder may be requested to provide the aforementioned data at the stage of the proposal evaluation.

Deliverables:

• Study report containing statistical analyses
• RNAseq data for each studied cell line (preferentially data is to be compatible with Cancer Cell Line Encyclopedia expression database developed by Broad Institute in CSV format)

The Ordering Party does not allow the submission of partial offers, i.e. for one, several or all of the above-mentioned tasks.

The study described in the task No. 1 shall be initiated no later than the end of November 2024. For tasks No. 2 and 3 results shall be delivered within 6-8 weeks from the date of cells seeding.

Not all items specified in the Cost proposal (Appendix No. 4) will be included in the upcoming orders. The final scope of work will be determined based on availability of desired cell lines (ex. selected indications) as well as based on the obtained initial results and current project needs. Therefore, they will appear as successive orders.

Conditions for participation in the proceedings

1. The contract may not be awarded to entities related to the Ordering Party personally or by capital. Capital or personal ties are understood as interrelationships between the Ordering Party and the Supplier or persons authorized to incur liabilities on behalf of the Ordering Party or persons performing on behalf of the Ordering Party activities related to the preparation and conduct of the Supplier selection procedure, consisting in particular of:
   1. participating in the company as a partner in a civil partnership or partnership,
   2. owning at least 10% of shares of stocks,
   3. acting as a member of the supervisory or management body, proxy, proxy,
   4. remaining in a marriage, relationship of kinship or affinity in a straight line, kinship of the second degree or affinity in the lateral line or in relation to adoption, care or guardianship.
      In order to meet this condition, the supplier is obliged to send, together with the offer, a signed Statement of the lack of connections (Appendix No. 1 to this RFP).
2. Orders cannot be awarded to:
   1. a Contractor referred to art. 7 sec. 1 indicated in lists specified in Regulation no 765/2006 and Regulation no 269/2014 or entered in list on basis of a decision on entry in the list deciding on application of measure referred to article 1 point 3 of the Act of April 13, 2022 on special solutions in field of counteracting supporting aggression against Ukraine (Polish Journal of Laws no 835).
   2. a Contractor whose beneficial owner within meaning of the Act of 1 March 2018 on counteracting money laundering and financing terrorism (Polish Journal of Laws no 593 and 655) is a person indicated in lists specified in Regulation 765/2006 and the Regulation 269/2014 or entered on  list or being such a beneficial owner from February 24, 2022, provided that it was entered on list on the basis of a decision on entry in the list determining application of measure referred to in art. 1 point 3 of the Act of April 13, 2022 on special solutions in field of counteracting supporting aggression against Ukraine (Polish Journal of Laws no 835);
   3. a Contractor whose parent undertaking or subsidiary entity within the meaning of Art. 3 sec. 1 point 37 and 39 of the Accounting Act of 29 September 1994 (Polish Journal of Laws no 217, 2105 and 2106) is an entity indicated in the lists specified in Regulation 765/2006 and Regulation 269/2014 or entered on the list or being such a parent undertaking from February 24, 2022, provided that it was entered on list on the basis of a decision on entry in list determining application of measure referred to in art. 1 point 3 of the Act of April 13, 2022 on special solutions in field of counteracting supporting aggression against Ukraine (Polish Journal of Laws no 835).
      In order to fulfill this condition a Tenderer is obliged to send with the offer signed statement (Appendix No. 2 to this RFP).  
3. The offer is addressed to bidders who have experience in providing similar services for at least 3 years. Experience should be demonstrated by attaching a declaration of meeting these criteria which constitutes Appendix 3. The Ordering Party reserves the right to ask the Bidder to submit additional documents and explanations confirming the information contained in the declaration (Appendix No. 3).

Proposal preparation

1. Each correspondence should include the number of the procedure in the subject line:
   RFP 025357 - IN VITRO EFFICACY STUDY IN A LARGE PANEL OF CANCER MODELS INCLUDING ORGANOID SCREEN Company name / Name
2. Deadline for submitting the offer is 16.07.2024 at 23:59. The date may change, about which all Suppliers will be informed.
3. The offer with all appendices can be placed on Adamed Procurement Platform SAP Ariba Network at https://supplier.ariba.com.
4. Each Tenderer may submit only one offer.
5. The Proposal should be prepared in Polish or English.
6. Prices in the offer should be net prices in polish zloty (PLN), euro (EUR),American dollar (USD) org Great Britain pound (GBP).
   Prices expressed in currencies other than PLN will be converted in accordance with the NBP exchange rate on the date of the end of the tender procedure. If the table of average NBP exchange rates is not published on the date of publication the exchange rate from the last table of average exchange rates published before the date of publication of the contract notice will be used.
7. The offer should contain at least the following information: Company name, address, TAX/registry number or ID number, number of the inquiry, net price, currency, payment terms (in days) and required appendices.
8. The cost estimate should be prepared in a spreadsheet file, attached as Appendix No. 4 to this request for proposal: Appendix_4_RFP_025357_Cost_Proposal_[CompanyName/Name]. In addition, the Bidder may prepare the bid in its own format. Bids without a completed Attachment No. 4 will not be considered.
9. Offer period validity should be not less than 90 days (from the end of submission deadline).
10. It is allowed to award selected Contractor supplementary contracts in accordance with basic contract subject, in the amount not exceeding 50% of basic contract value. 
11. The Tenderer bears all costs related to offer preparations. The Contracting Authority (Adamed Pharma) does not provide reimbursement of costs of participation in this procedure.

Selection criteria and method of evaluation of submitted offers

1. The Ordering Party has the right to reject an offer submitted by a Supplier that does not meet the conditions for participation in the procedure or if the offer is incomplete or inconsistent with this inquiry.

2. Criteria for selecting offers:

   1. Net price presented as the total cost of the services provided including deliverables described in the “Objects of the Contract” (criterion weight - 100% of the overall score)

   Criteria	Weight criterion[%]	Method of evaluation in accordance with the formula
   Net price of the sum of all  items indicated in the cost proposal (appx. no. 4)	100%	net price of the lowest offer / net price of the examined offer x 100 x 100% = number of points

3. The Ordering Party reserves the right to negotiate proposals with all the Bidders. Negotiations may have several consecutive  rounds  with  the  possibility  to  invite  the Bidders  to  submit  the updated quotation after each round of negotiations.

4. The offer with the highest final number of points will be considered the most advantageous.

5. The results of mathematical operations performed when evaluating the bids are rounded to two decimal places. In the event of receiving equal points for at least two offers the net price will be the decisive criterion.

Selection of the Contractor and manner of announcement:

1. The Ordering Party will select the most advantageous offer on the basis of the offer evaluation criteria specified in this inquiry.
2. The Ordering Party will inform about the results of this inquiry on the website  https://www.adamed.com/en/development-and-innovation/requests-for-proposals-and-tenders and will send them via SAP Ariba Platform to each Supplier who has submitted his offer.

Additional information about participation in the tender

1. Tender is available via the Adamed Group Purchasing Platform at: https://supplier.ariba.com and on website https://www.adamed.com/en/development-and-innovation/requests-for-proposals-and-tenders.
2. Username and password to log in to the Purchasing Platform will be sent to the Suppliers by the Operator by e-mail during registration.
3. Technical requirements. In order to work smoothly with the https://supplier.ariba.com Purchasing Platform, the user should have at least the following technical capabilities:
   • PC or MAC computer with a 1GHz or faster processor and at least 512 MB RAM,
   • permanent access to the Internet with a guaranteed bandwidth of not less than 1Mb/s,
   • Internet browser in the latest version. IE 9.0+ or Mozilla Firefox 24+ or Chrome 26+ or Safari 5+.
4. The tender procedure may be repeated only in case of inability to be carried out by the Operator or the Employer. Technical problems on the side of Suppliers will have no impact on the course of the tenders.
5. Prior to the tender procedure, it is advisable to familiarize yourself with the operating instructions of the Purchase Platform attached to the tender.
6. The start and finish dates and configuration of each stage of the tender will be presented on the Purchase Platform and may change, all interested Suppliers will be notified by the system by e-mail.
7. Technical support during the procedure. During the procedure, the Suppliers can obtain technical support at: +48 539 737 818 or in the Platform in the Help tab.

General provisions

1. The contracting authority reserves the right to cancel the procedure without giving any reason at any stage of the procedure.
2. In the event of cancellation of the procurement procedure, the contractors shall not be entitled to claim reimbursement of the costs of participation in the procedure.
3. By submitting an offer, you accept all terms and conditions of the procedure without any reservations.
4. Withdrawal by the Ordering Party from concluding the contract in the event of notifying the contractor about the selection of its offer, it may not be the basis for claims for the costs of participation in the procedure.
5. In the course of assessing the submitted applications, the Ordering Party may request the contractors to provide explanations regarding the content of the documents submitted by them.
6.  If the offer does not contain all the required elements, the Ordering Party may, in justified cases, call the Contractor to supplement it.
7.  The contracting authority reserves the right to record sound during technical meetings with suppliers. Sending the offer will be treated as giving consent to record the meetings.
8.  The Ordering Party allows the contract terms to be negotiated with the Contractor to a limited extent.
9. The Ordering party will sign a contract with the selected Contractor.
10. The Ordering Party provides for the possibility of introducing significant changes to the contract concluded as a result of the conducted contract award procedure in relation to the content of the offer, on the basis of which the contractor was selected, in the event of the necessity to change the scope of service indicated in the offer / agreed scope, resulting from:
    1. justified and required changes in the project documentation that were impossible to predict at the time of contract execution
    2. Requirement for performing of equivalent activities based on scientific reasons
    3. Financial limitations of Ordering Party resulting in limiting the scope of contracted activities
    4. Changes in the project activities resulting from consultations carried out with regulatory agencies/offices
    5. Any changes and additions to the contract concluded with the selected Contractor will be made in the form of written annexes to the contract signed by both parties.

Cooperation and communication in the course of preparing responses 

1. All questions related to the subject of this inquiry may be directed via email to: aleksandra.stojak@adamed.com, using an Excel file - Appendix No 5.
2. The list of required documents is available in Appendix No. 6.
3. The person authorized to contact the Suppliers on Monday-Friday from 08:00 am to 04:00 pm is: Aleksandra Stojak [aleksandra.stojak [at] adamed.com].

Appendix No 1  (download)

Appendix No 2  (download)

Appendix No 3  (download)

Appendix No 4  (download)

Appendix No 5  (download)

Appendix No 6  (download)

Creating an offer on the Portal SAP Ariba Network (download)

SAP Ariba Network registration (download)